Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Nektar Therapeutics (NKTR) Drug Pipeline

Drug pipeline
Drug NameConditionStageStatusStudy NameTrial Start DateArticle
RezpegaldesleukinModerate-To-Severe Atopic DermatitisPhase IIIRecruitingA Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic DermatitisJul 14, 2026
RezpegaldesleukinModerate-To-Severe Atopic DermatitisPhase IIIRecruitingA Phase 3 Study of Rezpegaldesleukin (NKTR-358) for Patients ≥ 12 Years of Age With Moderate-to-Severe Atopic DermatitisJul 02, 2026―
RezpegaldesleukinAlopecia AreataPhase IIActive Not RecruitingA Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Severe to Very Severe Alopecia Areata in Adult Patients (Rezolve AA)Mar 25, 2024―
RezpegaldesleukinModerate To Severe Atopic DermatitisPhase IIActive Not RecruitingA Phase 2b Study to Evaluate Rezpegaldesleukin (Rezpeg) in the Treatment of Adult Patients With Moderate-to-Severe Atopic DermatitisNov 13, 2023―
C-Til051Metastatic Non Small Cell Lung CancerPhase IRecruitingC-TIL051 in Non-Small Cell Lung CancerDec 07, 2022―
Nktr-255 At 1.5 Μg/Kg, Nktr-255 At 3.0 Μg/Kg, Nktr-255 At 3.0/6.0 Μg/KgNon-Hodgkin Lymphoma, Relapsed/Refractory Diffuse Large B-Cell Lymphomaphase2AndPhase3TerminatedNKTR-255 vs Placebo Following CD19-directed CAR-T Therapy in Patients With Relapsed/Refractory Large B-cell LymphomaDec 01, 2022―
Levocetirizine, Ly3471851HealthyPhase ICompletedA Phase I Study of LY3471851 in Healthy ParticipantsOct 03, 2022―
Ly3471851HealthyPhase ICompletedA Single-Dose Study of LY3471851 in Healthy ParticipantsAug 09, 2021―
Pembrolizumab, BempegaldesleukinMetastatic Head And Neck Cancer, Recurrent Head And Neck Cancerphase2AndPhase3TerminatedBEMPEG With Pembrolizumab vs Pembrolizumab Alone in Patients With Metastatic or Recurrent HNSCC (PROPEL-36)Jul 09, 2021―
Nivolumab, Nktr-214Rhabdomyosarcoma, Ependymoma, Ewing Sarcoma, High-Grade Glioma, Leukemia And Lymphoma, Medulloblastoma, Miscellaneous Brain Tumors, Miscellaneous Solid Tumors, Relapsed, Refractory Malignant Neoplasms, Neuroblastomaphase1AndPhase2TerminatedA Study of Bempegaldesleukin (BEMPEG: NKTR-214) in Combination With Nivolumab in Children, Adolescents and Young Adults With Recurrent or Treatment-resistant CancerJan 26, 2021―

FAQ

What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Nektar Therapeutics (CH:NKTR) have in its pipeline
Nektar Therapeutics CH:NKTR is currently developing the following drugs: Rezpegaldesleukin, C-Til051, Nktr-255 At 1.5 Μg/Kg, Nktr-255 At 3.0 Μg/Kg, Nktr-255 At 3.0/6.0 Μg/Kg, Levocetirizine, Ly3471851, Ly3471851, Pembrolizumab, Bempegaldesleukin, Nivolumab, Nktr-214, Standard Of Care, Bempegaldesleukin, Cetuximab, Nktr-255, Nivolumab, Cabozantinib, Axitinib, Nivolumab, Bempegaldesleukin, Nivolumab, Bempegaldesleukin, Radical Cystectomy, Daratumumab, Rituximab, Nktr-255, Nktr-255 Q21, Enzalutamide, Avelumab, Bempegaldesleukin, Talazoparib, Nivolumab, Bempegaldesleukin, ⁸⁹Zr-Df-Iab22m2c, Nktr-214, Tak-659, Nktr-181, Oxycodone Ir, Nivolumab, Cabozantinib, Sunitinib, Bempegaldesleukin, Bempegaldesleukin, Vb10.Neo, Nivolumab, Bempegaldesleukin, Nktr-262, Carboplatin, Cisplatin, Pembrolizumab, Paclitaxel, Pemetrexed, Nab Paclitaxel, Atezolizumab, Nktr-214, Dose Escalation Doublet: Combination Of Nktr-214 + Nivolumab, Dose Expansion Doublet: Combination Of Nktr-214 + Nivolumab, Schedule Finding Triplet: Combination Of Nktr-214+ Nivolumab+ Ipilimumab, Dose Expansion Triplet: Combination Of Nktr-214+ Nivolumab+ Ipilimumab, Gemcitabine, Paclitaxel, Docetaxel, Vinorelbine, Nab-Paclitaxel, Eribulin, Nktr-102, Ixabepilone, Nktr-214, Nktr-181 Bid Tablets, Nktr-102. These drug candidates are in various stages of clinical development as the company works toward FDA approval.